Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
IPO Year:
Exchange: NASDAQ
Website: gtglabs.com
ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and Genetic Technologies Limited (NASDAQ:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical prog
MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE, "Company", "GTG", or "Genetic Technologies")), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on October 2, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Genetic Technologies' senior leadership who will share insight into the Company's portfolio of genomics-based tests targeting health, wellness and serious disease, along with progress on its recent move to a capital light model. Genetic Technologies' EasyDNA platform has over $7m in annual recur
MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few years, CancerIQ has shown, in real-world breast imaging settings, that genetic testing uptake is increased when their platform is integrated into the operational pipeline within the imaging center
CHARLOTTE, N.C., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, is pleased to announce the global launch of the geneType™ Risk Assessment portfolio on our wholly owned EasyDNA platform currently selling in 42 countries, setting the stage for the potential significant expansion of the Company's current A$7.5m annual revenues. This expansion allows the Company to promote and sell its most powerful geneType™ innovation on its most profitable channel to realise more than 70% gross margin. This key step change in co
MELBOURNE, Australia, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE, "Company", "GTG", or "Genetic Technologies")), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on August 15, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature some of Genetic Technologies Senior Executives, who will share insight into the Company's portfolio of genomics-based tests targeting health, wellness and serious disease. Genetic Technologies' EasyDNA platform has over $7m in annual recurring revenues in the Paternity and Health and wellness spa
CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, has conducted an operations review and announces that it intends to transition to a capital light operations model – which is anticipated to result in an immediate material reduction in operating costs. This capital light operations model is intended to focus on sales growth (particularly in the Company's largest market in the United States) and move the Company's operations to an outsourced / collaborations approach (rather than the more expensive cu
MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years' experience operating across life sciences, technology and consumer segments that include senior finance leadership roles with major ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited. More r
CHARLOTTE, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, today announced the introduction of geneType's suite of genetic risk assessment tests to Canada and New Zealand. Dovetailing geneType's recent expansion to the US market under its partnership with health and wellness technology leader Stayhealthy, Inc ("Stayhealthy"), the company is expanding its international presence four-fold in the second quarter of 2024. The geneType risk assessment test distribution in the new territories will be directed by Stay
CHARLOTTE, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk and improving the health of populations worldwide. Since the geneType Risk Assessment Tests became available, GTG has tested a statistically significant number of people in Australia and the US. These results have revealed a compelling statistic: 79.5% of individuals tested*1 showed an elevated risk for at least one disease. GTG believes this is a significant finding driving increased surveillance and screening whi
CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, "Company", "GTG", or "Genetic Technologies"))), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on June 27, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Simon Morriss, CEO of Genetic Technologies, who will share insight into the Company's portfolio of genomics-based tests targeting health, wellness and serious disease, including the geneType multi-risk test. The team will provide an update on four pivotal strategies: Scal
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
20-F - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
SC 13G/A - GENETIC TECHNOLOGIES LTD (0001166272) (Subject)
SC 13G - GENETIC TECHNOLOGIES LTD (0001166272) (Subject)
GAINERS: Elixinol Wellness (OTC:ELLXF) shares closed up 56.67% at $0.00 Blueberries Medical (OTC:BBRRF) shares closed up 27.60% at $0.01 CNBX Pharmaceuticals (OTC:CNBX) shares closed up 25.00% at $0.01 Leafbuyer Techs (OTC:LBUY) shares closed up 22.50% at $0.02 Heritage Cannabis Holding (OTC:HERTF) shares closed up 19.27% at $0.00 iAnthus Capital Hldgs (OTC:ITHUF) shares closed up 16.34% at $0.02 Eastside Distilling (NASDAQ:EAST) shares closed up 10.88% at $0.95 Genetic Technologies (NASDAQ:GENE) shares closed up 8.41% at $0.80 Zoned Props (OTC:ZDPY) shares closed up 7.26% at $0.65 C21 Investments (OTC:CXXIF) shares closed up 6.38% at $0.28 SOL Glb Inv (OTC:SOLCF) shares closed up 6.27% at
GAINERS: Leafbuyer Techs (OTC:LBUY) shares closed up 3900.00% at $0.02 Heritage Cannabis Holding (OTC:HERTF) shares closed up 125.00% at $0.00 AusCann Group Holdings (OTC:ACNNF) shares closed up 50.00% at $0.01 Cann Gr (OTC:CNGGF) shares closed up 37.50% at $0.02 Target Group (OTC:CBDY) shares closed up 30.59% at $0.00 Canopy Gwth (NASDAQ:CGC) shares closed up 17.25% at $8.35 RIV Capital (OTC:CNPOF) shares closed up 13.33% at $0.10 GrowGeneration (NASDAQ:GRWG) shares closed up 13.03% at $2.66 Auxly Cannabis Group (OTC:CBWTF) shares closed up 12.60% at $0.03 SNDL (NASDAQ:SNDL) shares closed up 9.66% at $2.27 Aurora Cannabis (NASDAQ:ACB) shares closed up 8.87% at $6.25 Village Farms Intl (NAS
Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years' experience operating across life sciences, technology and consumer segments that include senior finance leadership roles with major ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited. More recently, in roles as an executive, interim or non-executive
GAINERS: Australis Capital (OTC:AUSAF) shares closed up 9900.00% at $0.01 Global Hemp Group (OTC:GBHPF) shares closed up 70.36% at $0.05 Maple Leaf Green World (OTC:MGWFF) shares closed up 68.48% at $0.05 CordovaCann (OTC:LVRLF) shares closed up 42.50% at $0.06 Target Group (OTC:CBDY) shares closed up 25.00% at $0.00 Blueberries Medical (OTC:BBRRF) shares closed up 19.09% at $0.01 CLS Holdings USA (OTC:CLSH) shares closed up 17.00% at $0.04 Zelira Therapeutics (OTC:ZLDAF) shares closed up 15.32% at $0.55 Leafbuyer Techs (OTC:LBUY) shares closed up 14.67% at $0.02 Canopy Gwth (NASDAQ:CGC) shares closed up 10.92% at $7.14 SOL Glb Inv (OTC:SOLCF) shares closed up 10.66% at $0.05 Cansortium (OT
GAINERS: Zelira Therapeutics (OTC:ZLDAF) shares closed up 69.95% at $0.48 Global Hemp Group (OTC:GBHPF) shares closed up 40.00% at $0.03 CordovaCann (OTC:LVRLF) shares closed up 29.03% at $0.04 Elixinol Wellness (OTC:ELLXF) shares closed up 25.00% at $0.00 Eastside Distilling (NASDAQ:EAST) shares closed up 23.57% at $1.20 Body and Mind (OTC:BMMJ) shares closed up 15.70% at $0.04 Pharmadrug (OTC:LMLLF) shares closed up 15.25% at $0.01 1933 Industries (OTC:TGIFF) shares closed up 14.86% at $0.01 Maple Leaf Green World (OTC:MGWFF) shares closed up 10.69% at $0.03 Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed up 10.42% at $58.92 Rocky Mountain High (OTC:RMHB) shares closed up 8.33% at $0.0
GAINERS: MJ Holdings (OTC:MJNE) shares closed up 44.44% at $0.00 CLS Holdings USA (OTC:CLSH) shares closed up 15.83% at $0.05 Maple Leaf Green World (OTC:MGWFF) shares closed up 11.28% at $0.03 Rocky Mountain High (OTC:RMHB) shares closed up 8.27% at $0.01 Charlottes Web Holdings (OTC:CWBHF) shares closed up 5.92% at $0.17 Greenlane Hldgs (NASDAQ:GNLN) shares closed up 5.88% at $0.26 Zoned Props (OTC:ZDPY) shares closed up 5.28% at $0.66 22nd Century Group (NASDAQ:XXII) shares closed up 4.09% at $0.71 Aurora Cannabis (NASDAQ:ACB) shares closed up 3.74% at $5.69 EnWave (OTC:NWVCF) shares closed up 3.57% at $0.17 Tilray Brands (NASDAQ:TLRY) shares closed up 3.41% at $1.83 Cara Therapeutics (N
GAINERS: Blueberries Medical (OTC:BBRRF) shares closed up 25.86% at $0.01 CV Sciences (OTC:CVSI) shares closed up 22.38% at $0.05 Global Hemp Group (OTC:GBHPF) shares closed up 20.88% at $0.02 Body and Mind (OTC:BMMJ) shares closed up 20.00% at $0.04 SOL Glb Inv (OTC:SOLCF) shares closed up 12.61% at $0.05 Leafbuyer Techs (OTC:LBUY) shares closed up 11.64% at $0.02 Aurora Cannabis (NASDAQ:ACB) shares closed up 8.69% at $5.35 Genetic Technologies (NASDAQ:GENE) shares closed up 6.20% at $1.31 Nextleaf Solutions (OTC:OILFF) shares closed up 5.44% at $0.07 Emeren Group (NYSE:SOL) shares closed up 5.18% at $1.58 1933 Industries (OTC:TGIFF) shares closed up 4.74% at $0.01 Auxly Cannabis Group (OT
Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, today announced the introduction of geneType's suite of genetic risk assessment tests to Canada and New Zealand. Dovetailing geneType's recent expansion to the US market under its partnership with health and wellness technology leader Stayhealthy, Inc ("Stayhealthy"), the company is expanding its international presence four-fold in the second quarter of 2024. The geneType risk assessment test distribution in the new territories will be directed by Stayhealthy Canada and Stayhealthy New Zealand, respectiv
GAINERS: GreenGro Technologies (OTC:GRNH) shares closed up 900.00% at $1e-05 CordovaCann (OTC:LVRLF) shares closed up 50.89% at $0.07 1933 Industries (OTC:TGIFF) shares closed up 47.06% at $0.01 Kaya Holdings (OTC:KAYS) shares closed up 29.70% at $0.04 Target Group (OTC:CBDY) shares closed up 24.28% at $0.00 Global Compliance (OTC:FUAPF) shares closed up 23.20% at $0.01 MJ Holdings (OTC:MJNE) shares closed up 22.41% at $0.00 CV Sciences (OTC:CVSI) shares closed up 19.77% at $0.06 Pharmadrug (OTC:LMLLF) shares closed up 11.11% at $0.01 4Front Ventures (OTC:FFNTF) shares closed up 10.95% at $0.07 Eastside Distilling (NASDAQ:EAST) shares closed up 7.29% at $0.97 Genetic Technologies (NASDAQ:GE
GAINERS: Plant Based Investment (OTC:CWWBF) shares closed up 9900.00% at $0.0001 Elixinol Wellness (OTC:ELLXF) shares closed up 26.00% at $0.00 Maple Leaf Green World (OTC:MGWFF) shares closed up 20.87% at $0.03 Global Hemp Group (OTC:GBHPF) shares closed up 10.82% at $0.04 Charlottes Web Holdings (OTC:CWBHF) shares closed up 10.58% at $0.20 1933 Industries (OTC:TGIFF) shares closed up 8.11% at $0.01 Trulieve Cannabis (OTC:TCNNF) shares closed up 6.16% at $10.51 22nd Century Group (NASDAQ:XXII) shares closed up 5.63% at $0.79 Zoned Props (OTC:ZDPY) shares closed up 5.26% at $0.65 RIV Capital (OTC:CNPOF) shares closed up 5.21% at $0.10 Cresco Labs (OTC:CRLBF) shares closed up 5.00% at $1.78
ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and Genetic Technologies Limited (NASDAQ:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical prog
ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Genetic Technologies: https://www.redchip.com/assets/access/gene_accessBioVie: https://www.redchip.com/assets/access/bivi_accessIn an exclusive interview, Simon Morriss, CEO of Genetic Technologies, appears on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV to provide a corp
ORLANDO, FL / ACCESSWIRE / December 29, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Genetic Technologies: https://www.redchip.com/assets/access/gene_accessBioVie: https://www.redchip.com/assets/access/bivi_accessIn an exclusive interview, Simon Morriss, CEO of Genetic Technologies, appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a
ORLANDO, FL / ACCESSWIRE / October 6, 2023 / RedChip Companies will air interviews with Knightscope, Inc. (NASDAQ:KSCP), Soligenix, Inc. (NASDAQ:SNGX), and Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) on The RedChip Small Stocks Big Money Show®, a sponsored program on Bloomberg TV, this Saturday, October 7, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Knightscope: https://www.redchip.com/assets/access/knightscope_access.htmlSoligenix: https://www.redchip.com/assets/access/sngx_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessWilliam Santana Li, CEO and Chair
ORLANDO, FL / ACCESSWIRE / September 15, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (OTC:ARDS), Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE), and American Resources Corporation (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 16, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessAmerican Resources: https://www.redchip.com/assets/access/arec_accessAbout The
MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to advise that RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and 60 Degrees Pharmaceuticals (60P) (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: • Genetic Technologies (NASDAQ:GENE): https://www.redchip.com/
ORLANDO, FL / ACCESSWIRE / September 1, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Genetic Technologies (NASDAQ:GENE): https://www.redchip.com/stocks/GENE60 Degrees Pharmaceuticals (NASDAQ:SXTP): https://www.redchip.com/stocks/SXTPAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations a
ORLANDO, FL / ACCESSWIRE / October 13, 2022 / RedChip Companies will air a new interview with Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) ("Company", "GTG"), a global leader in genomics-based tests in health, wellness, and serious disease, on The RedChip Money Report® on Bloomberg TV, this Saturday, October 15, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Genetic Technologies Limited's CEO Simon Morriss discusses the Company's expanded portfolio of tests, global relationships and partnerships, revenue growth channels, reported five consecutive quarters of gr
MELBOURNE, Australia, July 14, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that it has completed the acquisition of the direct-to-consumer eCommerce business and distribution rights associated with AffinityDNA as announced on May 16, 20221. Acquisition Highlights: Strategic acquisition strengthens the direct-to-consumer channel for GENE, building on the incremental EasyDNA expansion opportunities recently announced (ASX July 5, 20222).Provides additional platform for growth in the multibillion-dollar consumer geno
FORT LAUDERDALE, Fla., Sept. 9, 2021 /PRNewswire/ -- September 9, 2021–BelHealth Investment Partners, LLC ("BelHealth") is pleased to announce that it has completed the sale of assets of the international division of General Genetics Corporation (GGC), a provider of relationship and clinical genetic testing services, to Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE) is a diversified molecular diagnostics company ("GTG"). The transaction was structured in a combination of cash and stock of GTG. "We are pleased to see this transaction come to fruition," said Inder Tallur.Founded in 2013, GGC, managed its non-US based direct-to-consumer (DTC) genetic testing business consisting of trad
MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few years, CancerIQ has shown, in real-world breast imaging settings, that genetic testing uptake is increased when their platform is integrated into the operational pipeline within the imaging center
MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years' experience operating across life sciences, technology and consumer segments that include senior finance leadership roles with major ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited. More r
MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, "Company", "GTG"))), is pleased to announce the launch of a wide-reaching customer – targeted digital advertising campaign in the United States. This comprehensive program will drive Consumer Initiated Testing (CIT) for the company's geneType Risk Assessment Tests. The campaign will commence end of March 2024 and will scale up throughout the remainder of the year. The U.S. wellness testing market is projected to reach $4.9 billion by 2032 from $878.9 million in 2022 with an annual growth rate of 18.86%1. GTG's strategy ensures that the company's geneType Risk Assessment test portfolio will be
MELBOURNE, Australia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE), is at the forefront in personalised predictive genomics, reshaping the healthcare landscape with its inventive strategy for early disease detection and personalized wellness is pleased to share Business update for the quarter ending 31 December 2023 (Q2 FY24). GENE's pioneering initiatives in genomics-based tests place it at the forefront of precision medicine. Leading the world in risk prediction in oncology, cardiovascular, and metabolic diseases, Genetic Technologies continues to develop cutting edge risk assessment products to capitalize on the burgeoning clinical and consumer personali
MELBOURNE, Australia, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG", "GENE")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease, is pleased to report excellent commercial progress in the USA strategic operations with the following updates: Strategic Highlights: Active engagement with 11 US payer groups with an initial target list of 30 with coverage in tens of millions of livesEngagement with 19 US Concierge Medicine Practices with large volume pricing discussionsCommercial evaluations underway at 10 US medical/family practicesRe-engagement with 1,600 previous geneType US custo
MELBOURNE, Australia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results for the year ended June 30, 2022. It has been an exciting 12 months focused on our commercialisation journey. We now have the most comprehensive portfolio of genetic based tests available for individuals and animals. In addition to our patented geneType polygenic based risk tests, our portfolio includes pharmacogenomics, Non-Invasive Prenatal Testing (NIPT), carrier screen testing, oncogenetic diseases, and pet care. This year w
MELBOURNE, Australia, April 12, 2021 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company")), announces the appointment of Michael Tonroe to the role of Chief Financial Officer, commencing on 28 June 2021. Michael has over 25 years' experience in overseeing the finance function at both management and board-level positions for private and listed companies in Australia, UK, US and Canada. He also has extensive experience in the biotech space across both the financial and company secretary roles having most recently managed both functions for dual-listed Opthea Limited. Commenting on the appointment, Chairman, Peter Rubinstein said
MELBOURNE, Australia, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, the ‘Company’), announced today that they have entered into a three-year partnership agreement with mental health company, Taliaz, for the distribution rights of their PREDICTIX products in Australia, New Zealand and the USA (“Agreement”). Key Highlights Expands GTG’s product offering and establishes the mental health vertical through distribution partnership agreement harnessing PREDICTIX, Taliaz’s CE-registered, genomic-based, AI driven antidepressant selection technology that can improve today’s antidepressant prescribing accuracy by 47%4Potential